Quark Pharmaceuticals files for Nasdaq IPO

The Nes Ziona based drug development company plans raising $20 million.

Drug development company Quark Pharmaceuticals Inc. has filed a prospectus with the US Securities and Exchange Commission (SEC). According to the prospectus, the Nes Ziona-based company plans raising $20 million "as soon as practicable."

Quark president and CEO Dr. David Zurr founded the company in 1994. The company is developing silencing RNA (siRNA) drugs, which function by selectively blocking genes that cause disease. The Ness Ziona-based company has several drugs in the pipeline, aimed at treating age-related macular degeneration (AMD), acute kidney injury, and glaucoma. The company has raised $130 million in eight financing rounds to date, the most recent in June.

Quark has a licensing agreement with Pfizer for the commercialization of its ophthalmic treatments and an option agreement with Novartis for the commercialization of its kidney drug.

Published by Globes, Israel business news - www.globes-online.com - on September 26, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס